CD39 and CD73 as Promising Therapeutic Targets: What Could Be the Limitations?
Ana Maria Oliveira Battastini, Fabrício Figueiró, Daniela Bitencourt Rosa Leal, Pedro H. Doleski, Maria Rosa Chitolina Schetinger
Abstract
OPINION article Front. Pharmacol., 11 March 2021Sec. Experimental Pharmacology and Drug Discovery https://doi.org/10.3389/fphar.2021.633603
Topics & Concepts
MedicinePharmacologyComputational biologyIntensive care medicineChemistryBiologyAdenosine and Purinergic SignalingPharmacological Receptor Mechanisms and EffectsSynthesis and Biological Evaluation